Via Pharmaceuticals Stock Analysis
| VIAP Stock | USD 0.0005 0.00 0.00% |
Via Pharmaceuticals' financial leverage is the degree to which the firm utilizes its fixed-income securities and uses equity to finance projects. Companies with high leverage are usually considered to be at financial risk. Via Pharmaceuticals' financial risk is the risk to Via Pharmaceuticals stockholders that is caused by an increase in debt. In other words, with a high degree of financial leverage come high-interest payments, which usually reduce Earnings Per Share (EPS).
Given that Via Pharmaceuticals' debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Via Pharmaceuticals is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Via Pharmaceuticals to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Via Pharmaceuticals is said to be less leveraged. If creditors hold a majority of Via Pharmaceuticals' assets, the Company is said to be highly leveraged.
Via Pharmaceuticals is overvalued with Real Value of 4.2E-4 and Hype Value of 5.0E-4. The main objective of Via Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Via Pharmaceuticals is worth, separate from its market price. There are two main types of Via Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Via Pharmaceuticals stock is traded in the USA on OTCCE Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Via Pharmaceuticals is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day ( substitute day ), Independence Day. Via Stock trading window is adjusted to America/New York timezone.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Via Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. Via Stock Analysis Notes
The company has Price to Book (P/B) ratio of 1.89. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Via Pharmaceuticals recorded a loss per share of 0.01. The entity had not issued any dividends in recent years. The firm had 1:15 split on the 6th of June 2007. VIA Pharmaceuticals, Inc., a development stage biotechnology company, focuses on the development of compounds for the treatment of cardiovascular and metabolic diseases. The company was founded in 2004 and is headquartered in San Francisco, California. Via Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 6 people. For more information please call the company at 415 283 2200 or visit http://www.viapharmaceuticals.com.Via Pharmaceuticals Investment Alerts
| Via Pharmaceuticals generated a negative expected return over the last 90 days | |
| Via Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Via Pharmaceuticals currently holds 14 M in liabilities. Via Pharmaceuticals has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Via Pharmaceuticals' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (9.6 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Via Pharmaceuticals currently holds about 84 K in cash with (6.11 M) of positive cash flow from operations. |
Via Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 10.28 K.Technical Drivers
In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Via Pharmaceuticals, as well as the relationship between them.Via Pharmaceuticals Price Movement Analysis
Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in Via Pharmaceuticals price series with the more recent values given greater weights.
Via Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Via Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Via Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Via Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Flynn James E over a week ago Disposition of 1459 shares by Flynn James E of Via Pharmaceuticals at 3.9236 subject to Rule 16b-3 | ||
Anderson Richard L over six months ago Acquisition by Anderson Richard L of 20000 shares of Via Pharmaceuticals at 2.38 subject to Rule 16b-3 | ||
Craves Fred B over six months ago Acquisition by Craves Fred B of 3671806 shares of Via Pharmaceuticals at 0.071 subject to Rule 16b-3 | ||
Flynn James E over six months ago Disposition of 259 shares by Flynn James E of Via Pharmaceuticals at 3.9799 subject to Rule 16b-3 | ||
Olukotun Adeoye Y over six months ago Acquisition by Olukotun Adeoye Y of 55758 shares of Via Pharmaceuticals at 0.03 subject to Rule 16b-3 |
Via Pharmaceuticals Outstanding Bonds
Via Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Via Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Via bonds can be classified according to their maturity, which is the date when Via Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| VIACOM INC 6875 Corp BondUS925524AX89 | View | |
| VIACOM INC 55 Corp BondUS925524AV24 | View | |
| VTRS 23 22 JUN 27 Corp BondUS92556VAC00 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| VIACOMCBS INC Corp BondUS92556HAB33 | View | |
| VIACOMCBS INC Corp BondUS92556HAC16 | View | |
| VIACOMCBS INC Corp BondUS92556HAD98 | View |
Via Pharmaceuticals Debt to Cash Allocation
Via Pharmaceuticals currently holds 14 M in liabilities. Via Pharmaceuticals has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Via Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.Via Pharmaceuticals Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Via Pharmaceuticals' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Via Pharmaceuticals, which in turn will lower the firm's financial flexibility.Via Pharmaceuticals Corporate Bonds Issued
About Via Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Via Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Via shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Via Pharmaceuticals. By using and applying Via Stock analysis, traders can create a robust methodology for identifying Via entry and exit points for their positions.
VIA Pharmaceuticals, Inc., a development stage biotechnology company, focuses on the development of compounds for the treatment of cardiovascular and metabolic diseases. The company was founded in 2004 and is headquartered in San Francisco, California. Via Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 6 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Via Pharmaceuticals to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Idea Analyzer Now
Idea AnalyzerAnalyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
| All Next | Launch Module |
Additional Tools for Via Stock Analysis
When running Via Pharmaceuticals' price analysis, check to measure Via Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Via Pharmaceuticals is operating at the current time. Most of Via Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Via Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Via Pharmaceuticals' price. Additionally, you may evaluate how the addition of Via Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.